Discover how AI labs are reshaping R&D by integrating machine learning, robotics, and smart data systems to accelerate ...

Lydon claims that he came up with the idea for the logo in the shape of a pill, and asked Morris to use his design tools to finish off the image. But Morris claims he alone suggested using the ...

Revenues came in at $13.59 billion, missing Wall Street's estimates of $13.76 billion. In this photo illustration, the AstraZeneca logo is displayed on a smartphone screen with a stock market chart in ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up to $1 billion, expanding its treatments for cancer. EsoBiotec's ...

Image Credit: sasirin pamai/Shutterstock.com Click here to read more from AstraZeneca: Early Diagnosis and Intervention in Heart Failure with Prof. Martin Cowie & Dr. Lisa Anderson To start ...

TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at $66.64. Discover outperforming stocks and invest ...

The company is already working with multiple large hospitals in the U.S. and Israel, as well as drug companies, including AstraZeneca and Pfizer. Promise Bio is now emerging from stealth with a ...

Bloomberg / Contributor / Getty Images A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a ...

AstraZeneca’s booming oncology business has won over cancer patient groups. Having languished down the leaderboard in the past, the drugmaker vaulted (PDF) over many rivals in PatientView’s ...